Tuesday, August 4, 2015

Ranbaxy halts production of its generic Lipitor after another recall

Ranbaxy Pharmaceuticals has halted productions of its generic version of the cholesterol drug Lipitor after recalling a second batch of tablets.

Ranbaxy halts production of its generic Lipitor after another recall

0 comments

Ranbaxy Pharmaceuticals has halted productions of its generic version of the cholesterol drug Lipitor after recalling a second batch of tablets in the 10mg, 20mg, and 40mg dosage strengths.

The lots of atorvastatin (the chemical name) are packaged in bottles of 90 and 500 tablets, and are being recalled due to “possible contamination with very small glass particles similar to the size of a grain of sand (less than 1 mm in size),” according to the U.S. Food and Drug Administration.

Ranbaxy, which is among the biggest sellers of generic Lipitor, is based in India but has its U.S. headquarters in Princeton.

The FDA said it is working with other manufacturers of atorvastatin to ensure adequate supplies and avoid a shortage.

The company said it had no reports of patients experiencing adverse effects, but it could not rule out the possibility.

Ranbaxy has had previous productions problems. The Justice Department got involved and the company is working under a consent decree .

"Americans expect and deserve safe, effective, and high quality medications," the FDA said in its statement on the Ranbaxy recall. "The FDA continues to evaluate information associated with this recall and will notify the public as new information becomes available. The agency will continue to oversee the recall process, and work with the Ranbaxy to resolve these pharmaceutical quality issues."

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Also on Philly.com:
letter icon Newsletter